
The FDA approved adrabetadex for infantile-onset NPC based on a 55% lower risk of death vs external controls, with a boxed warning for hearing loss.
Although ESR is the more widely used test, most data suggest CRP is actually the more valuable of the two in the diagnosis and management of many inflammatory conditions.






